Patellar Tendon Regeneration With Platelet-rich Plasma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The central third of the patellar tendon is used as a donor site for anterior cruciate ligament (ACL) reconstruction. After months or years the harvest site partially regenerates. The regeneration process is accomplished by biological mechanisms,including cells and proteins known as growth factors. The platelets are natural reservoirs of growth factors, and a platelet concentrate known as Platelet-Rich Plasma (PRP) has a three to five fold increase in growth factors. The hypothesis of the study is that the PRP can improve the regeneration of the patellar tendon.
The platelets are obtained from the patient's blood through a filtration system called apheresis, with the use of 250 milliliters of blood, with a sterile system. All the others components of blood (red cells, plasma, white cells) returns to the patient. The PRP is then applied in the harvest site on the patellar tendon, at the end of ACL reconstruction.
The patients are randomized in two groups, one with the use of PRP and the other group without PRP. This information for the patients will be granted just at the end of the research. After the surgery the rehabilitation protocol is the same for both groups. An isokinetic testing is done before the surgery and after six months. Questionnaires about the knee function are asked before the surgery and after six months. A magnetic resonance imaging is performed after six months to evaluate the tendon regeneration.
| Condition | Intervention | Phase |
|---|---|---|
|
Knee Instability |
Procedure: Platelet-rich plasma Procedure: Control group |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Regeneration of the Patellar Tendon After Harvesting Its Central Third With Platelet-rich Plasma. Prospective and Randomized Study. |
- Evaluation of the patellar tendon regeneration with magnetic resonance imaging. [ Time Frame: Six months ] [ Designated as safety issue: No ]Six months after the surgery a magnetic resonance imaging will be done to evaluate the regeneration of the patellar tendon donor site. The area of the gap, related to the tendon harvest, will be measured and compared between the groups.
- Isokinetic testing and questionaires. [ Time Frame: Six months ] [ Designated as safety issue: No ]Six months after the surgery, patients will answer to questionaires about their knee function and do an isokinetic testing to evaluate their muscle strength. The results will be compared between the groups.
| Enrollment: | 27 |
| Study Start Date: | November 2008 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: PRP
In this group PRP will be used in the patellar tendon donor site.
|
Procedure: Platelet-rich plasma
Intra-operative use of platelet-rich plasma in the patellar tendon after harvesting its central third for ACL reconstruction.
Other Names:
|
|
Sham Comparator: Control
In this group PRP will not be aded to the patellar tendon donor site
|
Procedure: Control group
In this group PRP will not be added to the patellar tendon donor site at the end of ACL reconstruction.
Other Names:
|
Eligibility| Ages Eligible for Study: | up to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- indication of anterior cruciate ligament surgery with patellar ligament
- skeletal maturity
Exclusion Criteria:
- other knee ligament injuries
- severe chondral lesions
- osteoarthritis
- non-compliance to the rehabilitation
- previous surgery in the affected knee
- reoperation during the time of the study for an unrelated condition
- infection
Contacts and Locations| Principal Investigator: | Adriano M Almeida, MD | Instituto de Ortopedia e Traumatologia - HCFMUSP - São Paulo, Brazil |
| Study Director: | Arnaldo J Hernandez, MD, PhD | Instituto de Ortopedia e Traumatologia - HCFMUSP - São Paulo, Brazil |
More Information
Publications:
| Responsible Party: | University of Sao Paulo General Hospital |
| ClinicalTrials.gov Identifier: | NCT01111747 History of Changes |
| Other Study ID Numbers: | 0162/08, CaPPesqHCFMUSP 0162/2008 |
| Study First Received: | April 26, 2010 |
| Last Updated: | March 13, 2012 |
| Health Authority: | Brazil: National Health Surveillance Agency |
Keywords provided by University of Sao Paulo General Hospital:
|
platelet-rich plasma patellar ligament regeneration growth substances |
Additional relevant MeSH terms:
|
Mitogens Mitosis Modulators Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 16, 2013